Thursday, 21 February 2019

Connective Tissue Disease Market Pipeline Review, 2018- Identify Key Business Opportunities

Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue diseases market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.
Key Players
Some of key the players in the market are Abbott Laboratories, Bayer AG, F. Hoffmann-La Roche Ltd, Pfizer, AutoImmune Inc., Johnson & Johnson, Amgen Inc., AstraZeneca, Eli Lilly and Company, Biogen, LUPIN, and others.
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 
Browse Complete 85 Pages Premium Research Report Enabled with 66 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/connective-tissue-disease-market-4977

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Augmented Bone Graft Market Anticipated To Witness Noteworthy Growth in the Coming Years

According to the British Editorial Society of Bone & Joint Surgery, bone is the second most common transplanted tissue after blood with an estimated 2.2 million grafting procedures worldwide annually as recorded in 2015. This development has been fuelled by the increasing cases of fractures and accidents around the world.
The Global market of Augmented Bone Graft is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.
Augment Bone Graft is a combination drug/device product used for repairing the bone and reviving its regenerative properties. It is used as an alternative to autograft in arthrodesis of the ankle or hindfoot indicating the need for supplemental graft material. The use of augment bone graft eliminates the need for a second surgery to harvest autologous bone, thereby avoiding donor site morbidity. According to the National Health Interview Survey, in 2012, around 126 million adults were affected by this disease in the U.S. According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases.
Allografts and bovine-derived bone graft products dominate the augmented bone graft market. These materials have variations in particle size which is their main drawback. The recent technological trend is to replace these natural materials with alloplastic bone grafts such as ceramics and polymers as they can be manufactured to the precise size and characteristics.
There has been increasing acceptance of bone grafting procedures which drives the market for augmented bone graft products. Many healthcare professionals have started using these bone grafts, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for augmented bone graft. These bone graft works in a unique way to stimulate three key processes of early bone healing.
Various other factors such as, increasing advancement in technology, and rising adoption rate of new technology continuously contribute to the growth of this market. Despite these developments, high cost of surgeries and ethical issues related with bone grafting procedures may hamper the growth of the market. For instance, a study conducted by BMC Medical Ethics states that in a sample of 100 patients, about 20% of the patients refuse to accept allografts for their grafting surgery.
Additionally, stringent regulations obstruct the growth of bone grafts market and inadequate reimbursement policies for bone grafting also hampers the growth of global bone grafts market. Rapid product launches and increasing mergers and acquisitions between bone graft systems manufacturing companies are some of the major trends in the global bone grafts market.
The Key Players
  • Zimmer Holdings, Inc.
  • BioMimetic Therapeutics LLC
  • Wright Medical Technology, Inc.
  • Stryker Corporation, Smith & Nephew Plc
  • RTI Surgical, Inc.,
  • Olympus Biotech Corporation
  • NuVasive, Inc.
  • NovaBone Products LLC
  • Medtronic, Inc.
  • LifeNet Health, Inc.
  • Integra LifeSciences Holdings Corporation
  • Exactech, Inc.
  • DePuy Spine, Inc.
  • Synthes Inc.
  • DePuy Synthes Companies
  • Biomet, Inc.
Segmentation
The Augmented Bone Graft is segmented on the basis of products, application, and end-users.
On the basis of application, the market is segmented into the Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, and Spinal Fusion
On the basis of product, the market is segmented into the Allografts, Bone Grafts Substitutes, and Cell-based Matrices. The Allografts segment is further sub divided into Machined Allografts and Demineralized Bone Matrix. The Bone Grafts Substitutes is also sub categorized as Bone Morphogenic Proteins (BMP) and Synthetic Bone Grafts.
On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others.
Regional Analysis
The Global Augmented Bone Graft Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global augmented bone graft market owing to the increasing healthcare expenditure in North America since 2016. Canadian healthcare specifically was stressed by an advancing demographic move. The increase of insurance coverage because of health care reform (Affordable Care Act) in the United States additionally prompted an expansion in health care spending. In 2016, healthcare organizations found liberation from a special tax on medical devices (Medical Device Excise Tax). The United States Congress put off the tax for a long two years in 2015.
For Europe, the healthcare spending has expanded slightly in Germany. Neverthelss, the orthopedic biologics market including the bone graft substitute market has been determined by solid strong competition and price pressure. While volume of sales and the scope of new treatment techniques are on the ascent, net revenues in the German market are declining. Western Europe continues to see a need to save money on healthcare because of a slight drop in financial growth and obstinate economic pressure.
Healthcare spending in Asia expanded in 2016 due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
Furthermore in the Middle East & Africa the spending for healthcare was also increased. This was essentially because of elections in a few nations, (for example, Ghana, Niger, Uganda, Zambia and Somalia), healthcare growth and population growth. Awareness for medicinal technology likewise expanded extraordinarily. Due to of low local production, the region is dependent on imported medicinal products. The import standard in numerous nations is 80% to 90%.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/augmented-bone-graft-market-4961  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Wednesday, 20 February 2019

Current and forthcoming Anti-Hypertensive Drugs Market size in terms of volume and value 2018

The rising incidence of hypertension is closely related to sedentary lifestyle and unhealthy eating patterns. The expansion of the market is also effectively supported by the improved detection methods as well as the availability of better drugs for the treatment of the condition. Increased research and development activities to improve overall drug qualities such as its efficacy is expected to boost the progress of the market in the upcoming period.
The market is projected to attain revenues touching $ 38.9 billion by 2022 while expanding at a CAGR of 2.73% approximately in the forecast period.
Segmental Analysis
The segmentation of the anti-hypertensive drugs market is carried out on the basis of pharmacological class, hypertension type, region and disease source. On the basis of pharmacological class, the market is segmented into ACE Inhibitors, diuretics, adrenergic blocker, calcium channel blockers among others. The regions included in the market comprise of Europe, North America, Europe, Asia Pacific and rest of the world. On the basis of hypertension type, the anti-hypertensive drugs market is segmented into pulmonary hypertension drugs and systemic drugs. on the basis of disease source, the market is segmented into primary and secondary.
Regional Analysis 
The regional analysis of the market comprises of Europe, North America, Europe, Asia Pacific and rest of the world. Globally, the North American region is the principal market for anti-hypertensive drugs. The European region is the next major market for anti-hypertensive drugs. The advanced regions will govern the approaching future market for anti-hypertensive drugs with emerging regions in a supporting role only. However, the emerging region's market especially the Asia Pacific region will be the swiftest rising and is expected to be central to the development of the market in the coming forecast period.
Competitive Analysis
The central contenders in the global anti- hypertensive drugs market are Astra Zeneca plc, Pfizer Inc., Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Takeda Pharmaceuticals Company Limited, Novartis AG and Ranbaxy Laboratories Limited, Inc.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @  https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Handheld Surgical Devices Market Revenue, Opportunity, Forecast and Value Chain 2018

The hand held surgical devices are specially designed for specific surgeries. These are available in a wide variety of shapes and sizes.
Increasing number of surgical procedures is the key factor driving the handheld surgical devices market. According to the Australian Institute of Health and Welfare, during 2015–16, there were 10.6 million hospitalisations, and 1 in 4 hospitalisations involved a surgical procedure.
Key players
Some of the key players in the global handheld surgical devices market are B. Braun Melsungen AG, Integra LifeSciences Corporation, Zimmer Biomet Holdings, Pelion Surgical, Medtronic, Smith & Nephew, Johnson & Johnson, Millennium Surgical Corp, Medicon Eg, Elite Medical, Becton, Dickinson and Company (BD), Thompson Surgical, Stryker, Aspen Surgical, KLS Martin, CooperSurgical Inc., and others.
Segmentation
The global handheld surgical devices market is segmented based on application, product, end user and region.
The global market for handheld surgical devices, by application is segmented into neurology, urology, orthopedics, gynecology, cardiovascular, wound closure, and others.
The market, by product, is segmented into forceps and spatulas, retractors, dilators, graspers, auxiliary devices, cutter devices, and others. The auxiliary devices segment is further classified as clamps, cannulas, and closure devices. The cutter devices segment is further classified as trocars, lancets, and scissor. The others segment includes punches, curettes, blunt dissectors, and snares.
Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centres, research and academic institutes, and others. Clinics held a lucrative market share in 2017 due to rising prevalence of chronic conditions.
Regional Analysis
The Americas dominated the global market for handheld surgical devices owing to the increasing prevalence of chronic conditions, and high geriatric population.
In 2017, it was estimated that Europe stood second in the global handheld surgical devices market. This can be attributed to the increasing cases of surgical procedures, and rising research and development investments. According to the 2016 data suggested by Eurostat, around 1040.8 cases of cataract surgery and 406.2 cases of transluminal coronary angioplasty are registered in Germany.
Asia Pacific was projected to be the fastest growing region in 2017. Factors such as growing healthcare sector, increasing penetration of the market players within the region, increasing healthcare expenditure, a rising number of surgical procedures drive the regional markets of the Asia Pacific region. On the other hand, the Middle East and Africa held least share in the global handheld surgical devices market due to the low per capita income, especially within the African region.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/handheld-surgical-devices-market-7210

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Oncology Information Systems Market Segments, Opportunity, Growth and Forecast by End-use Industry 2018

Global oncology information systems (OIS) market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 2,356.6 million in 2017 and is projected to grow at a CAGR of 7.5% during the forecast period. OIS is a comprehensive information and image management solution that facilitates the management of patient treatment schedules, treatment plans, treatment delivery, and treatment summaries. This system involves the exchange of information between radiation therapy departments and the healthcare enterprises. Factors attributed for the market growth are worldwide growing geriatric population along with rising prevalence of cancer, increasing investments in cancer research, and technological advancements in OIS. The International Agency for Research on Cancer (IARC) stated that there were 14 million new cases of cancer in 2012, that grew to 17.0 million in 2018, which is anticipated to reach to more than 22 million by 2030. Progress in developing treatments is enabling investors to invest in oncology research. Increasing equity investments in cancer-therapeutics startups is foreseen to shape the OIS vertical in the near future. On the contrary, higher costs associated with OIS services are anticipated to restrain the market growth over the forecast period.
Key players
Accuray Incorporated, Cerner Corporation, Philips Healthcare, McKesson Corporation, Altos Solutions, Inc., Elekta AB, Varian Medical Systems, Inc., Flatiron Health, Inc., RaySearch Laboratories, Epic Systems Corporation, Bogardus Medical Systems, Inc., and CureMD Healthcare are some of the prominent players in the global oncology information systems market.
Segmentation
The global oncology information systems market has been segmented into product & service type, application, and end user.
By product & service type, the market has been segmented into software and professional services. The software segment is further categorized into patient information systems and treatment planning systems. The professional services segment is further divided into consulting/optimization services, implementation services, and post-sale & maintenance services. The software for patient information systems segment spearheaded the market in 2017 as these systems offer advantages including planned treatment and remote access due to digital availability as compared to conventional record maintenance methods.
On the basis of application, the market has been classified into medical oncology, radiation oncology, and surgical oncology. The medical oncology segment would lead the market over the forecast period owing to rising applications of OIS in efficiently managing, interpreting, analyzing, and storing the patient information, as well as, in predicting the treatment results for patients, thereby improving their survival rates.
Based on end user, the market has been categorized into hospitals & oncology clinics, government institutes, and research centers.
The global oncology information systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The oncology information systems market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European oncology information systems market has been segmented into Western Europe and Eastern Europe. The Western Europe oncology information systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The oncology information systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The oncology information systems market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Analysis
Geographically, the Americas would grab the highest market share over the forecast period due to the presence of oncology information systems providers, changing lifestyle coupled with rising burden of cancer, increasing expenditure on healthcare, and adoption of oncology information systems in the US and Canada. The IARC reported that in 2018, the Americas have 13.3% of the global population and accounted for 21.0% of incidence and 14.4% of mortality worldwide.
The oncology information systems market in the Middle East & Africa will exhibit considerable market growth rate from 2018 to 2023. Majority of the regional market is likely to govern by the Middle East region due to the presence of world-class cancer treatment centers in Dubai, Saudi Arabia, increasing healthcare sector reforms, and gradually rising investments in OIS sector.
Growing adoption of OIS in European countries, namely, UK, Germany, France, Italy, and Spain, as the major market value contributors such as Philips Healthcare, Elekta AB, and RaySearch Laboratories are headquartered in the region.
Asia-Pacific would represent the phenomenal growth during the forecast period due to growing elderly population coupled with rising prevalence of cancer. The World Health Organization (WHO) and IARC reported that the proportions of cancer deaths in Asia (57.3%) are higher than the proportions of incident cases (48.4%) due to the higher frequency of certain cancer types associated with poorer prognosis and higher mortality rates.
Browse Complete 90  Pages Premium Research Report Enabled with 81 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/oncology-information-systems-market-7080

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Biochips Market - Granular Market Report and Review, 2018

Market Scenario:
Global Biochips market is expected to grow significantly over the forecast period. The market held a market value of USD 7,300 million in 2017 and is projected to grow at a CAGR of 16.6% over the forecast period. Biochips are intended to function in biological environment, preferably inside living organism.
The factors such as increasing technological advancements in biochips is the major driving factor for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer genomics. Furthermore, growing applications of biochips will boost the market growth during forecast period. For instance, biochips can perform thousands of biological reactions operations in few seconds.   
However, high cost of the instruments and stringent regulatory guidelines may restrain the growth of the market.
According to national Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.
Key players:Perkinelmer, Inc., Fluidigm Corporation, Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., Cepheid Inc., Illumina, Inc., GE Healthcare, Thermo Fisher Scientific, Inc, Roche Diagnostics are some of the prominent players in the global biochips market.
Segmentation:The Global Biochips Market has been segmented into type, technology, and end user.
By type, the market has been segmented into DNA chips, lab-on-a-chip, protein chips, cell arrays, and tissue arrays. DNA chips is further segmented into gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, drug discovery, agricultural biotechnology, and others. Lab-on-a-chip is further segmented into clinical diagnostics, genomics, IVD (In-Vitro Diagnostic) & POC (Point of care), Proteomics, Drug Discovery, and others. Protein chips is further segmented into proteomics, expression profiling, diagnostics, high-throughput screening, drug discovery, others.
Based on technology, the market has been segmented into microarrays and microfluidics.
The biochips market, by end user, has been segmented into biotechnology and pharmaceutical companies, hospitals and diagnostics centers, academic & research institutes, and others.
The global biochips market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biochips market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.      
The European biochips market has been segmented into Western Europe and Eastern Europe. The Western Europe biochips market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.       
The biochips market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biochips market in the Middle East & Africa has been segmented into the Middle East and Africa.       
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global biochips market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.
Europe is expected to hold the second largest position in the global biochips market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).
The biochips market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biomedical and biotechnology sector and growing number of target population in the region.  
The Middle East & Africa has the lowest share of the global biochips market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.  
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/biochips-market-7063

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Surgical Retractors Market to Observe Significant Growth by 2018

Retractors are surgical instrument which are used to separate the edges of the wound or surgical incision.
The factors such as increasing number of surgical procedures is the major driving factor for the market. Beside this technological advances and improved surgical treatment with increased success rate has provided fuel for the growth of the market. Cost of surgery and surgical products may restrain the growth of the market.
According to WHO, in 2015, more than 35% of the total global population were suffering from major or minor cardiovascular complication and in 2014, globally 39% of adults aged 18 years and over were overweight whereas 13% were obese.
Global Surgical Retractors Market is expected to grow significantly over the forecast period. The market held a market value of USD 1,103 million in 2017 and is projected to grow at a CAGR of 7.8% over the forecast period.
Key players:
Terumo Corporation, Henry Schein, INC., Johnson & Johnson, Medtronic, Becton, Dickinson and Company, Stryker Corporation, Globus Medical, INC., B. Braun Melsungen AG, Teleflex Incorporated, Integra Lifesciences Holdings Corporation, The Cooper Companies, INC., RTI Surgical, INC., Arthrex, Inc., Invuity, Inc., Medline Industries, Inc. are some of the prominent players in the global surgical retractors market.            
Segmentation:
The European Surgical Retractors Market has been segmented into Western Europe and Eastern Europe. The Western Europe surgical retractors market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.     The Surgical Retractors Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The surgical retractors market in the Middle East & Africa has been segmented into the Middle East and Africa.    
The Global Surgical Retractors Market has been segmented into product type, design, product usage, application, and end user. By product type, the market has been segmented into hand retractors, self-retaining retractors, table-mounted retractors, wire retractors, and accessories.Based on design, the market has been segmented into fixed or flat frame retractors, angled or curved frame retractors, and blade or elevated-tipped retractors. Based on product usage, the market has been segmented into tissue handling and dissection and fluid swabbing.
Based on application, the market has been segmented into obstetric & gynaecological, urological, abdominal, cardiothoracic, orthopaedic, head, neck, and spinal, aesthetic surgical, and others. The market, by end user, has been segmented into hospitals and surgical centres, ambulatory care centres, and others.The Global Surgical Retractors Market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The surgical retractors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.     
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global surgical retractors market owing to the high domestic income, and presence of major market players. According to the US Investments in Medical and Health Research and Development 2013-2015, a report by Research America, in 2015, total US medical and health R&D in the US was USD 158.7 billion.  
Europe is expected to hold the second largest position in the global surgical retractors market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).
The Surgical Retractors Market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing patient population and growing focus of major market players in the region.
The Middle East & Africa has the lowest share of the global surgical retractors market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.  
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/surgical-retractors-market-7019
            

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)